The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.

Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P

The American journal of gastroenterology1 Nov 2000Cited by 134 (Europe PMC)

PMID11095353DOI10.1111/j.1572-0241.2000.03210.xPepBankPUB-11095353

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In neuroendocrine tumors, lanreotide produced two objective responses among 39 evaluable patients, a 5% response rate.
In plain wordsIn neuroendocrine tumours, two of 39 evaluable lanreotide-treated patients had objective responses, a 5% response rate.
Peptide
Lanreotide
Outcome
Not applicableObjective response
Study
n = 39
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 14 days for symptomatic tumors or every 10 days for nonsymptomatic tumors · intramuscular · mean 12 months in symptomatic tumors and 13 months in nonsymptomatic tumorsAs given in this study (human).
Measurements
Objective response rate
5%
39 evaluable patients, 2 objective responses
Objective responses
2 patients
39 evaluable patients
Source sentences
Summary
Among the 39 evaluable patients, two objective responses were obtained, giving an objective response rate of 5% (one in the group with symptomatic tumors and one in the other group).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 46 patients were enrolled in this open, prospective, phase II trial.
Summary · context
They received lanreotide 30 mg i.m. every 14 days for 6 months when they had symptomatic carcinoid tumors, and lanreotide 30 mg i.m. every 10 days if they had nonsymptomatic tumors.
Report a problemFND-1109535301
02HumanNon-randomized trialEfficacy outcome
In symptomatic neuroendocrine tumors, one patient had an objective response to lanreotide.
In plain wordsIn symptomatic neuroendocrine tumours, one patient had an objective response to lanreotide.
Peptide
Lanreotide
Outcome
Not applicableObjective response in symptomatic tumors
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 14 days · intramuscular · mean 12 monthsAs given in this study (human).
Measurements
Objective responses
1 patients
symptomatic tumors
Source sentences
Summary
Among the 39 evaluable patients, two objective responses were obtained, giving an objective response rate of 5% (one in the group with symptomatic tumors and one in the other group).
4 context sentences(design, population, supporting numbers)
Summary · context
In all, 30 patients had symptomatic neuroendocrine tumors and 16 had asymptomatic neuroendocrine tumors.
Summary · context
Five patients in the group with symptomatic tumors and two in the group with nonsymptomatic tumors were considered not to be evaluable.
Summary · context
A total of 46 patients were enrolled in this open, prospective, phase II trial.
Summary · context
They received lanreotide 30 mg i.m. every 14 days for 6 months when they had symptomatic carcinoid tumors, and lanreotide 30 mg i.m. every 10 days if they had nonsymptomatic tumors.
Report a problemFND-1109535302
03HumanNon-randomized trialEfficacy outcome
In nonsymptomatic neuroendocrine tumors, one patient had an objective response to lanreotide.
In plain wordsIn nonsymptomatic neuroendocrine tumours, one patient had an objective response to lanreotide.
Peptide
Lanreotide
Outcome
Not applicableObjective response in nonsymptomatic tumors
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 10 days · intramuscular · mean 13 monthsAs given in this study (human).
Measurements
Objective responses
1 patients
nonsymptomatic tumors
Source sentences
Summary
Among the 39 evaluable patients, two objective responses were obtained, giving an objective response rate of 5% (one in the group with symptomatic tumors and one in the other group).
4 context sentences(design, population, supporting numbers)
Summary · context
In all, 30 patients had symptomatic neuroendocrine tumors and 16 had asymptomatic neuroendocrine tumors.
Summary · context
Five patients in the group with symptomatic tumors and two in the group with nonsymptomatic tumors were considered not to be evaluable.
Summary · context
A total of 46 patients were enrolled in this open, prospective, phase II trial.
Summary · context
They received lanreotide 30 mg i.m. every 14 days for 6 months when they had symptomatic carcinoid tumors, and lanreotide 30 mg i.m. every 10 days if they had nonsymptomatic tumors.
Report a problemFND-1109535303
04HumanNon-randomized trialEfficacy outcome
In neuroendocrine tumors, 19 lanreotide-treated patients had no significant tumor size increase for a mean of 9.5 months.
In plain wordsIn neuroendocrine tumours, 19 lanreotide-treated patients had no significant tumour growth for an average of 9.5 months.
Peptide
Lanreotide
Outcome
Not applicableTumor size stabilization
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 14 days for symptomatic tumors or every 10 days for nonsymptomatic tumors · intramuscular · mean 12 months in symptomatic tumors and 13 months in nonsymptomatic tumorsAs given in this study (human).
Measurements
Patients with no significant increase in tumor size
19 patients
neuroendocrine tumors
Mean duration without significant tumor size increase
9.5 months
neuroendocrine tumors
Source sentences
Summary
Nineteen patients had no significant increase in their tumor size for a mean of 9.5 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 46 patients were enrolled in this open, prospective, phase II trial.
Summary · context
They received lanreotide 30 mg i.m. every 14 days for 6 months when they had symptomatic carcinoid tumors, and lanreotide 30 mg i.m. every 10 days if they had nonsymptomatic tumors.
Report a problemFND-1109535304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.